Results 1 to 10 of about 390,088 (309)

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice [PDF]

International Journal of Retina and Vitreous
Purpose To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD).
Jorge Ruiz-Medrano, Iulia Pana, María García-Zamora, Ignacio Flores-Moreno, Mariluz Puertas, José Mª Ruiz-Moreno   +5 more
doaj   +3 more sources

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice [PDF]

Ophthalmology and Therapy
Introduction Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD).
Eloi Debourdeau, Helene Beylerian, Vuong Nguyen, Daniel Barthelmes, Mark Gillies, Pierre Henry Gabrielle, Stela Vujosevic, Louise Otoole, Martin Puzo, Catherine Creuzot-Garcher, Benjamin Wolff, Vincent Daien, The Fight Retinal Blindness! Study Group   +12 more
doaj   +3 more sources

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration [PDF]

International Journal of Retina and Vitreous, 2021
Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin, Asem Mohamed, Cristian Munteanu, Isabel Weinstein, Achim Langenbucher, Berthold Seitz, Shady Suffo   +6 more
doaj   +3 more sources

Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [PDF]

Ophthalmology and Therapy, 2023
Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang, Tso-Ting Lai, Chang-Hao Yang, Yi-Ting Hsieh   +3 more
doaj   +3 more sources

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients [PDF]

Vision, 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
Adrian Skelly, Vladimir Bezlyak, Gerald Liew, Elisabeth Kap, Alexandros Sagkriotis   +4 more
doaj   +5 more sources

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result [PDF]

Pharmaceuticals, 2023
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi   +6 more
doaj   +4 more sources

Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

Ophthalmology, 2023
PURPOSE To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2/vascular endothelial growth factor (VEGF)-A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend-based regimen (T&E) with up to ...
T. Wong, Z. Haskova, Kemal Asik, Caroline R. Baumal, Karl G. Csaky, N. Eter, Jane A. Ives, Glenn J. Jaffe, Jean-François Korobelnik, Hugh Lin, Toshinori Murata, Paisan Ruamviboonsuk, P. Schlottmann, A. Seres, David Silverman, Xiaodong Sun, Yannan Tang, J. A. Wells, Young Hee Yoon, C. Wykoff   +19 more
semanticscholar   +2 more sources

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen [PDF]

Scientific Reports, 2022
The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE ...
Yuki Hirata, Akio Oishi, Yuki Maekawa, Eiko Tsuiki, Akira Machida, Junko Kurihara, Takashi Kitaoka   +6 more
doaj   +4 more sources

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. [PDF]

Invest Ophthalmol Vis Sci, 2023
Purpose Radiation retinopathy (RR)-related macular edema commonly causes poor visual acuity outcomes in patients previously treated with ocular radiation therapy. Current treatments are not US Food and Drug Administration (FDA)-approved and prior studies
Trejo Corona S, Villanueva Boone C, Ali AM, Moore C, Brown A, Munoz J, Aaberg T, Schefler AC, ARRT Study Group.   +8 more
europepmc   +2 more sources

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema [PDF]

Scientific Reports, 2021
This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct
Takao Hirano, Yuichi Toriyama, Y. Takamura, M. Sugimoto, T. Nagaoka, Yoshimi Sugiura, F. Okamoto, Michiyuki Saito, K. Noda, S. Yoshida, A. Ishibazawa, Osamu Sawada, T. Murata   +12 more
semanticscholar   +4 more sources